SR9238

CAS No. 1416153-62-2

SR9238 ( —— )

Catalog No. M26825 CAS No. 1416153-62-2

SR9238 is a synthetic agonist of liver X receptor inverse (IC50s: 214 nM and 43 nM for LXRα and LXRβ, respectively).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 37 In Stock
5MG 60 In Stock
10MG 105 In Stock
25MG 213 In Stock
50MG 375 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SR9238
  • Note
    Research use only, not for human use.
  • Brief Description
    SR9238 is a synthetic agonist of liver X receptor inverse (IC50s: 214 nM and 43 nM for LXRα and LXRβ, respectively).
  • Description
    SR9238 is a synthetic agonist of liver X receptor inverse (IC50s: 214 nM and 43 nM for LXRα and LXRβ, respectively).(In Vitro):SR9238 effectively suppresses transcription from a fatty acid synthase promoter-driven luciferase reporter. SR9238 is a synthetic LXR inverse agonist (IC50s: 214 nM and 43 nM for LXRα and LXRβ, respectively). SR9238-induced recruitment of CoRNR box peptides is dose-dependent for both LXRα and LXRβ. It is found that SR9238 induces increased interaction of CoRNR box peptides derived from NCoR with both LXRα and LXRβ while causing decreased interaction with a coactivator NR box peptide derived from TRAP220. HepG2 cells treated with SR9238 cause a significant decrease in Fasn and Srebp1c mRNA expression.(In Vivo):SR9238 treatment inhibits diet-induced hepatosteatosis, hepatic inflammation, and hepatocellular injury. SR9238 is also detected in the intestine with either i.p. or oral administration. Approximately SR9238 (6 μM) is detected in the liver 2h after the injection of SR9238, but no compound is detected in the plasma. SR9238-treated mice show greatly reduced lipid content in the liver. Both Tnfa and Il1b expression are substantially reduced (~80% and >95%, respectively) in the SR9238-treated mice when compared to the vehicle-treated mice. SR9238-treated DIO mice display a considerably lower intensity of F4/80 staining versus vehicle-treated DIO mice consistent with a beneficial effect of SR9238 on non-alcoholic steatohepatitis. SR9238 treatment does not alter body weight or percent body fat composition relative to vehicle-treated animals during the experiment.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    NMDA receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1416153-62-2
  • Formula Weight
    595.7
  • Molecular Formula
    C31H33NO7S2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CCOC(=O)c1ccc(CN(Cc2ccc(cc2)-c2cccc(c2)S(C)(=O)=O)S(=O)(=O)c2c(C)cc(C)cc2C)o1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Costa BM, et al. A novel family of negative and positive allosteric modulators of NMDA receptors. J Pharmacol Exp Ther. 2010 Dec;335(3):614-21.
molnova catalog
related products
  • Gimeracil

    An inhibitor of dihydropyrimidine dehydrogenase, degrades pyrimidine including 5-fluorouracil in the blood.

  • TCS PrP Inhibitor 13

    TCS PrP Inhibitor 13 is an antiprion agent inhibiting protease-resistant prion protein (PrP-res) accumulation.

  • Lucyoside B

    Lucyoside B is a natural product from Luffa cylindrica ROEM.